Company Name:Allakos, Inc.
CEO: Robert Alexander

Sector: Health Technology

Exchange: NASDAQ

Country: US

Description: Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.

Key numbers

Market Capitalization:4293155449
Shares Outstanding: 48913700
Float: 25053695
Next Earning Date:2020-11-17
TTm EPS: -2.3517
TTm Dividend Rate:
200 days moving average:75.38
50 days moving average: 76.92
One day percent Change: 2.46

2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2016-12-31, 2017-12-31, 2018-12-31,
2016-12-31, 2017-12-31, 2018-12-31,